Cargando…

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy

INTRODUCTION: Combination therapy using immuno‐oncology drugs with tyrosine kinase inhibitors is increasingly important in the therapeutic strategy for metastatic renal cell carcinomas. Here, we report a case of metastatic renal cell carcinoma that was successfully treated with deferred cytoreductiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Hiroaki, Sazuka, Tomokazu, Fujimoto, Ayumi, Kagitani, Sakurako, Arai, Takayuki, Goto, Yusuke, Imamura, Yusuke, Sakamoto, Shinichi, Ikeda, Jun‐Ichiro, Ichikawa, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151202/
https://www.ncbi.nlm.nih.gov/pubmed/37144081
http://dx.doi.org/10.1002/iju5.12584
_version_ 1785035489007370240
author Sato, Hiroaki
Sazuka, Tomokazu
Fujimoto, Ayumi
Kagitani, Sakurako
Arai, Takayuki
Goto, Yusuke
Imamura, Yusuke
Sakamoto, Shinichi
Ikeda, Jun‐Ichiro
Ichikawa, Tomohiko
author_facet Sato, Hiroaki
Sazuka, Tomokazu
Fujimoto, Ayumi
Kagitani, Sakurako
Arai, Takayuki
Goto, Yusuke
Imamura, Yusuke
Sakamoto, Shinichi
Ikeda, Jun‐Ichiro
Ichikawa, Tomohiko
author_sort Sato, Hiroaki
collection PubMed
description INTRODUCTION: Combination therapy using immuno‐oncology drugs with tyrosine kinase inhibitors is increasingly important in the therapeutic strategy for metastatic renal cell carcinomas. Here, we report a case of metastatic renal cell carcinoma that was successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. CASE PRESENTATION: A 49‐year‐old man was referred to our hospital with a diagnosis of advanced right kidney cancer with multiple lung metastases (cT3aN0M1). The size of the primary tumor was so huge that it exceeded 20 cm in diameter, pushing the liver and intestines to the left. After administration of lenvatinib and pembrolizumab combination as first‐line treatment, all the metastatic lung lesions disappeared, and the primary lesion shrank significantly. Robot‐assisted radical nephrectomy was successfully performed, resulting in complete surgical remission. CONCLUSION: Deferred cytoreductive nephrectomy following a lenvatinib plus pembrolizumab combination is a useful therapeutic strategy for achieving complete remission of metastatic renal cell carcinomas.
format Online
Article
Text
id pubmed-10151202
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101512022023-05-03 A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy Sato, Hiroaki Sazuka, Tomokazu Fujimoto, Ayumi Kagitani, Sakurako Arai, Takayuki Goto, Yusuke Imamura, Yusuke Sakamoto, Shinichi Ikeda, Jun‐Ichiro Ichikawa, Tomohiko IJU Case Rep Case Reports INTRODUCTION: Combination therapy using immuno‐oncology drugs with tyrosine kinase inhibitors is increasingly important in the therapeutic strategy for metastatic renal cell carcinomas. Here, we report a case of metastatic renal cell carcinoma that was successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. CASE PRESENTATION: A 49‐year‐old man was referred to our hospital with a diagnosis of advanced right kidney cancer with multiple lung metastases (cT3aN0M1). The size of the primary tumor was so huge that it exceeded 20 cm in diameter, pushing the liver and intestines to the left. After administration of lenvatinib and pembrolizumab combination as first‐line treatment, all the metastatic lung lesions disappeared, and the primary lesion shrank significantly. Robot‐assisted radical nephrectomy was successfully performed, resulting in complete surgical remission. CONCLUSION: Deferred cytoreductive nephrectomy following a lenvatinib plus pembrolizumab combination is a useful therapeutic strategy for achieving complete remission of metastatic renal cell carcinomas. John Wiley and Sons Inc. 2023-03-19 /pmc/articles/PMC10151202/ /pubmed/37144081 http://dx.doi.org/10.1002/iju5.12584 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Sato, Hiroaki
Sazuka, Tomokazu
Fujimoto, Ayumi
Kagitani, Sakurako
Arai, Takayuki
Goto, Yusuke
Imamura, Yusuke
Sakamoto, Shinichi
Ikeda, Jun‐Ichiro
Ichikawa, Tomohiko
A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title_full A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title_fullStr A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title_full_unstemmed A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title_short A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
title_sort case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151202/
https://www.ncbi.nlm.nih.gov/pubmed/37144081
http://dx.doi.org/10.1002/iju5.12584
work_keys_str_mv AT satohiroaki acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT sazukatomokazu acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT fujimotoayumi acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT kagitanisakurako acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT araitakayuki acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT gotoyusuke acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT imamurayusuke acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT sakamotoshinichi acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT ikedajunichiro acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT ichikawatomohiko acaseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT satohiroaki caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT sazukatomokazu caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT fujimotoayumi caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT kagitanisakurako caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT araitakayuki caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT gotoyusuke caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT imamurayusuke caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT sakamotoshinichi caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT ikedajunichiro caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy
AT ichikawatomohiko caseofmetastaticrenalcellcarcinomasuccessfullytreatedwithdeferredcytoreductivenephrectomyfollowinglenvatinibpluspembrolizumabcombinationtherapy